Skip to main content

COVID 19 Updates from RheumNow

Baricitinib Therapy in Covid-19 Pneumonia

The NEJM has published the results of the ACCT-2 Study,  a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.

Paucity of Effectiveness Research on Telemedicine in RA

A systematic review of telehealth in delivering equivalent care in rheumatoid arthritis (RA) patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face (F2F) care; thus despite current widespread use there is a great need for credible well-desi

NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19

The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.

RWCS Highlights - Day 3

Today I’ve included some research and clinical pearls as well as fodder for your post COVID-19 dinner party or trivia night!  Enjoy!

Psoriatic Arthritis: 2020 Year in Review: with Drs. Alexis Ogdie, Artie Kavanaugh, and Eric Ruderman

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease (RMD) patients, based on the efforts of the North American Task force.

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,

IVIg in MIS-C

Among children with multisystem inflammatory syndrome (MIS-C), treatment with IVIG and methylprednisolone vs IVIG alone was associated with a more favorable fever course. MIS-C is a rare but serious pediatric condition associated with COVID-19 where different body parts can become inflamed, inclu

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Hydroxychloroquine Fails to Prevent COVID-19

There is a preponderance and mounting evidence that hydroxychloroquine (HCQ) is ineffective in COVID-19 infection; and now the NEJM reports a the results of a trial where HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy pe

Adverse Events with Anti-malarials during the COVID Pandemic

For a variety of reasons, the use of anti-malarials (chloroquine and hydroxychloroquine) rose dramatically in the pandemic; notable was the lack of proven benefit and the dramatic risk in reported adverse drug reactions (ADRs) associated with these drugs being used to treat SARS-CoV-2.

Consults in Cars

In this episode of Dialing for Doctors (AKA Tales of Telehell), we will consider a growing subset of telehealth seekers connecting from their cars.

I don’t mean they are driving to the clinic, or driving to a virtual care center.  

RheumNow Podcast – Rheumatology Burnout (1.29.2021)

Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com.

Social

Data Safety committee has closed recruitment to the colchicine arm in the RECOVERY trial a UK study of outcomes in COVID-19. Among 11162 enrolled pts (2178 deaths) those Rx w/ Colchicine had same 28 day mortality as usual care (20% vs. 19%) https://t.co/8gUc8LAZTp

Dr. John Cush @RheumNow ( View Tweet )

1 month ago
News Feature: Baricitinib Therapy in Covid-19 Pneumonia https://t.co/b3tsLcoXay https://t.co/tjqkk1RLFZ
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
Influenza Numbers are way down this year due to COVID mitigation methods, school/office closings, reduced travel/mobility. As of Jan 31st only 155 hospitalized with the flu (98% less than 2019-2020 flu season - 8,633 people were hospitalized with the flu) https://t.co/6c2YQKbt57?

Dr. John Cush @RheumNow ( View Tweet )

1 month ago
GSKs RCT showed otilimab (investigational anti-GM-CSF Ab) in severe COVID-19, was not superior to SOC for the primary endpoint - the proportion alive and free of respiratory failure at 28 days (but was effective in pts >70 yrs (65% vs 46%) https://t.co/OHvWGGlgKv

Dr. John Cush @RheumNow ( View Tweet )

1 month 1 week ago
News Feature: NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19 https://t.co/IrKnTlPDpK https://t.co/8topsI3nQN
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Top February Tweet: ACR Task Force published guidelines on RMD drug use w/ COVID vaccines. My views: 1. I agree, no change most DMARD, biologics 2. I disagree; I would NOT hold Orencia, I would NOT hold JAKi 3. I disagree: I would not hold MTX https://t.co/uSPfvJB8EC https://t.co/unOY1jvzTJ
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Its sill not SAFE! Avoid congregate settings! CDC report shows among 81 who participated in indoor high-intensity exercise classes - 68% developed COVID-19. 40% with COVID-19 attended class on day Sxs began. Most (76%) wore masks infrequently https://t.co/KLZauJUupN

Dr. John Cush @RheumNow ( View Tweet )

1 month 1 week ago
In Israel (as of Feb 2021) 84% of those ≥70 years and 10% for <50 years have received 2 doses of the COVID Vaccine; as such the need for mechanical ventilation in the elderly has declined 67% with the implementation of COVID vaccines. https://t.co/9Qnv72QYUS

Dr. John Cush @RheumNow ( View Tweet )

1 month 1 week ago
My Experience as a COVID19 Vaccine Trial Participant https://t.co/ILfXLUL8IZ

Dr. John Cush @RheumNow ( View Tweet )

1 month 1 week ago
Email Survey study of HSS rheumatic pts 7,094 responded 1,547 were women (18-50yrs) & 61 (4%) were pregnant during COVID. COVID prevalence was similar in PREG vs nonPREG (8% vs.9% ), PREG COVID pts had shorter Sxs, more loss taste/smell. https://t.co/4HDuXbZVrs

Dr. John Cush @RheumNow ( View Tweet )

1 month 3 weeks ago
×